The research team began with a deceptively simple question: which parts of the turnip actually matter for metabolism? Rather than testing a crude extract and stopping there, the investigators employed an activity-guided purification strategy. They ground ten kilograms of dried turnip root, extracted it with ethanol, and then partitioned the resulting material into fractions of increasing chemical refinement. Each fraction was tested in a laboratory model of insulin resistance: HepG2 liver cells bathed in high glucose and palmitic acid, a fatty acid that mimics the lipid overload seen in obesity and diabetes. The researchers measured how much glucose the cells could absorb, a direct readout of insulin sensitivity, and systematically eliminated fractions that showed no activity or toxicity.

The purification funnel narrowed dramatically. Of the two major fractions produced by liquid-liquid partitioning, the n-butanol fraction outperformed the water fraction at promoting glucose uptake. Silica gel chromatography then split this fraction into five subfractions, one of which, designated T-2D, stood out clearly. A second round of reversed-phase chromatography generated four refined subfractions, and the winner was unambiguous: T-3B drove glucose uptake in insulin-resistant hepatocytes to the highest levels observed in the entire screening campaign, reaching nearly 6.9 millimolar under the assay conditions, all without harming cell viability. This stepwise approach, the authors argue, addresses a persistent weakness in natural product research, where crude mixtures and single isolated compounds are often studied in isolation, leaving the interactions among constituents undefined.

With the active fraction in hand, the team moved to animal testing. They used db/db mice, a classic spontaneous model of type 2 diabetes in which animals carry a mutation that renders them obese, insulin resistant, and dyslipidemic. Mice with fasting blood glucose above 11.1 millimolar were randomized into groups receiving either a low dose of T-3B, a high dose, the anti-diabetic drug rosiglitazone as a positive control, or vehicle alone. Treatment was delivered by daily oral gavage for eight consecutive weeks, with body weight, food intake, and fasting glucose tracked weekly throughout.

The metabolic improvements were substantial and, in several respects, dose-dependent. High-dose T-3B lowered fasting blood glucose significantly as early as the second week of treatment, while the low dose produced significant effects by week three. Oral glucose tolerance tests performed after eight weeks showed that treated mice cleared a glucose load far more efficiently than untreated diabetic controls, with the high-dose group’s area under the glucose curve rivaling that of the rosiglitazone group. Insulin tolerance tests confirmed that the treated animals had genuinely recovered sensitivity to the hormone, not merely altered some downstream glucose metric. Body weight and food intake also declined moderately in treated mice, beginning around the sixth week of intervention.

Blood chemistry added another layer of benefit. Circulating levels of glucagon-like peptide-1, or GLP-1, an incretin hormone secreted by intestinal cells that promotes insulin release and satiety, were markedly depressed in the untreated diabetic mice but substantially restored by T-3B treatment. The fraction also corrected the characteristic diabetic lipid profile: plasma triglycerides, total cholesterol, and low-density lipoprotein all fell at the high dose, while high-density lipoprotein rose at both doses tested. Because elevated triglycerides and LDL cholesterol contribute to atherosclerotic risk in diabetic patients, the authors note that this dual glucose-and-lipid effect is exactly the profile sought in next-generation metabolic therapies, and one that many existing drugs only partially achieve.

The liver emerged as the fraction’s primary target organ. Histological staining revealed that untreated db/db mice livers were riddled with fat droplets, with ballooned hepatocytes and disordered tissue architecture, hallmarks of non-alcoholic fatty liver disease. T-3B treatment visibly reversed this steatosis, and biochemical assays confirmed reduced hepatic triglyceride content. Intriguingly, hepatic glycogen, the storage form of glucose, increased significantly in treated mice, while skeletal muscle glycogen remained unchanged, sharpening the picture of a liver-specific mechanism. The researchers propose that this matters because hepatic insulin resistance is an early and central driver of type 2 diabetes: when the liver stops responding to insulin, it churns out glucose uncontrollably while simultaneously importing fatty acids that worsen fat accumulation, creating a self-reinforcing vicious cycle between lipid deposition and metabolic dysfunction.

Molecular and genomic analyses converged on two well-known signaling hubs. Western blotting showed that diabetic mouse livers had blunted phosphorylation of the insulin receptor beta, insulin receptor substrate 1, AKT, and AMPK alpha, the canonical cascade through which insulin instructs the liver to store glucose and cease glucose production. Eight weeks of T-3B treatment rescued these phosphorylation defects in a dose-dependent manner, and parallel experiments in insulin-resistant HepG2 cells reproduced the effect within twenty-four hours. RNA sequencing of liver tissue reinforced the story at the transcriptomic level: more than 1,600 genes changed expression after treatment, with downregulated genes enriched in inflammatory pathways such as NF-kappaB and TNF signaling, oxidative stress responses, and cellular senescence, while upregulated genes clustered in fatty acid oxidation, the PPAR pathway, glycogen biosynthesis, and AMPK signaling itself.

Chemical fingerprinting of T-3B by high-performance liquid chromatography coupled with mass spectrometry and nuclear magnetic resonance identified six monomeric constituents: trans-4-hydroxycinnamic acid, chrysin, ferulic acid, trans-ferulic acid, 4-hydroxy-3,5-dimethoxycinnamic acid, and apigenin. When each was tested individually in insulin-resistant liver cells at twenty micromolar, chrysin and apigenin proved the strongest promoters of glucose uptake, with chrysin the single most potent compound despite not being the most abundant. Combining chrysin and apigenin produced an enhanced effect beyond simple addition, which the authors attribute to their shared flavone backbone and complementary regulatory pathways. Chrysin alone also reduced triglyceride and cholesterol accumulation in fat-injured liver cells, lowered markers of cellular damage, boosted the antioxidant enzyme superoxide dismutase, and reduced malondialdehyde, a marker of oxidative injury.

The authors are careful to flag the limits of their work. The reduced food intake observed in treated mice could partly confound the metabolic benefits, and the team acknowledges that pair-fed control groups would be needed to fully disentangle direct drug effects from dietary restriction. The signaling findings, while consistent, remain correlative without inhibitor or gene-knockdown experiments, the transcriptomic results await validation by quantitative PCR, and the absolute quantities and purity of the individual monomers were not fully quantified. The mechanism behind the restored GLP-1 secretion, whether direct stimulation of intestinal cells, gut signaling, or microbiome remodeling, also remains speculative. Still, the study delivers something the field has lacked: a defined, purified turnip fraction with a mapped component-pathway-phenotype network connecting specific flavones to insulin and energy-sensing signaling in the liver. As diabetes prevalence in China now exceeds twelve percent, well above the global average, and drug side effects push patients toward dietary alternatives, the prospect that a common vegetable harbors multi-target metabolic activity is a finding worth watching closely.

Subject of Research: Bioactive turnip compounds as potential treatments for type 2 diabetes and hepatic insulin resistance

Article Title: Bioactive components from Turnip improve liver and systemic metabolic homeostasis in mice with T2DM

Article References: Ling, Z., Jin, L., Xu, W., Sun, M., Sun, J., Zhou, Z., Liu, Q., Wang, Y., Liu, J., Wu, J., Khattab, O. M., Fu, H., Shou, Q., & Han, J. (2026). Bioactive components from Turnip improve liver and systemic metabolic homeostasis in mice with T2DM. Journal of Agriculture and Food Research, 31, Article 103344. https://doi.org/10.1016/j.jafr.2026.103344

Image Credits: AI Generated

DOI: Not provided

Keywords: turnip, type 2 diabetes, chrysin, apigenin, insulin resistance, liver metabolism, db/db mice, AMPK, PI3K-AKT, flavonoids, GLP-1, fatty liver disease

The biological rationale behind the study rests on the well-established role of HPV16 in cervical carcinogenesis. Persistent infection with high-risk HPV types is the major cause of cervical cancer worldwide, and the viral oncoproteins E6 and E7 are the principal effectors of that transformation. E6 promotes the ubiquitin-mediated degradation of the p53 tumor suppressor, disabling a cell’s primary safeguard against DNA damage and uncontrolled proliferation, while E7 disrupts the retinoblastoma protein pathway. Beyond these canonical functions, the viral oncoproteins also reshape the landscape of microRNA expression in infected cells. MicroRNAs are short, non-coding RNA molecules that regulate gene expression after transcription by binding target messenger RNAs and suppressing their translation or promoting their degradation. Because a single microRNA can influence dozens of targets, shifts in microRNA profiles can ripple across entire signaling networks, and viral manipulation of these regulators is increasingly recognized as a hallmark of HPV-associated cancers.

To test whether chrysin could counteract these effects, the team treated CaSki cells, a cervical cancer cell line that carries integrated HPV16 DNA, alongside normal human dermal fibroblasts as a non-cancerous comparison. The cells were exposed to chrysin across a concentration range of 31.5 to 500 micrograms per milliliter for two exposure periods of 24 and 48 hours. Cell viability was measured using the MTT assay, a colorimetric method in which metabolically active cells convert a yellow tetrazolium salt into a purple formazan product, allowing the proportion of surviving cells to be quantified. The researchers then quantified the expression of five selected microRNAs, miR-34a, miR-218, miR-20a, miR-195, and miR-23b, by quantitative reverse transcription polymerase chain reaction, calculating relative expression with the 2 to the power of negative delta delta Ct method. Levels of the HPV16 E6 protein were assessed by Western blotting, which separates proteins by molecular weight and detects the target with specific antibodies.

The viability results were striking for their selectivity. Chrysin reduced the survival of CaSki cells in a dose- and time-dependent manner, but it showed minimal toxicity toward the normal dermal fibroblasts at the same concentrations, yielding a high selectivity index. This therapeutic window matters because many candidate anticancer compounds fail precisely at this hurdle, killing tumor cells and healthy tissue alike. A high selectivity index suggests that the compound’s cytotoxic mechanisms preferentially target vulnerabilities present in the cancer cells, such as the altered survival signaling and metabolic rewiring characteristic of HPV-transformed lines, rather than general cellular processes shared by all dividing cells.

The microRNA findings provided the study’s most detailed molecular picture. After chrysin treatment, miR-34a expression rose approximately 10.05-fold compared with untreated controls, a change that reached a statistical significance level of P less than 0.0001. miR-218 increased 5.64-fold with P less than 0.01, and miR-20a showed a more moderate 1.7-fold increase with P less than 0.05. In contrast, miR-195 expression fell to 0.18-fold of control levels with P less than 0.01, while miR-23b showed no statistically significant change. Each of these microRNAs has documented connections to cancer biology. miR-34a is a transcriptional target of p53 and one of the best-characterized tumor-suppressive microRNAs, and previous work has shown that the HPV E6 oncoprotein interrupts its expression, effectively severing a p53-dependent regulatory arm. The restoration of miR-34a after chrysin treatment is therefore consistent with the concurrent reduction in E6 protein that the team observed.

miR-218, the second most strongly induced microRNA in the study, functions as a tumor suppressor in cervical cancer, where it has been shown to inhibit epithelial-to-mesenchymal transition, migration, and invasion by targeting genes such as SFMBT1 and DCUN1D1 and by acting within the SLIT/ROBO signaling pathway. Its fivefold increase after chrysin exposure suggests that the flavonoid may reinforce anti-metastatic regulatory circuits in addition to affecting viral oncoprotein abundance. The moderate rise in miR-20a is more nuanced, because members of the miR-17-92 cluster to which it belongs can behave as oncomiRs in some contexts while showing context-dependent effects in others. The decrease in miR-195, which has been reported to play roles in gynecological cancers with both tumor-suppressive and proliferative implications depending on setting, likewise underscores that microRNA responses to phytochemicals are not uniformly one-directional and require interpretation against specific cellular backgrounds.

Perhaps the most consequential measurement was the Western blot result for the viral oncoprotein itself. Chrysin-treated CaSki cells showed a significant reduction in HPV16 E6 protein levels, with treated samples measuring 0.64 relative to untreated controls, a difference significant at P less than 0.001. Because E6 is the viral factor responsible for targeting p53 for degradation, lowering E6 abundance could, in principle, allow p53-dependent tumor-suppressive programs to partially recover. The observed tenfold induction of miR-34a, a canonical p53-responsive microRNA, fits this interpretation, although the study’s design establishes association rather than a fully mapped causal chain. The authors are careful to frame the findings accordingly, noting that the concurrent modulation of E6 and several cancer-related microRNAs indicates a link but that the underlying pathways remain to be clarified.

The study also situates itself within a broader research effort on chrysin, a flavone with the chemical name 5,7-dihydroxyflavone. Prior investigations have documented apoptotic effects of chrysin in various human cancer cell lines, selective antiproliferative and antimigratory activity across a panel of cervical cancer-derived lines, inhibition of HeLa cell propagation through attenuation of cell survival signaling, and induction of both intrinsic and extrinsic apoptosis in ovarian cancer cells delivered via chrysin-loaded micelles. Chrysin has also been reported to alter microRNA expression in gastric cancer cells, suggesting that modulation of post-transcriptional regulation may be a recurring feature of its anticancer activity. At the same time, the compound faces a familiar obstacle for polyphenolic phytochemicals: poor aqueous solubility and limited bioavailability, which have motivated formulation strategies such as nanoparticle and micellar delivery systems in recent preclinical work.

For the cervical cancer field specifically, the results contribute to an emerging interest in natural products as sources of multi-target agents against HPV-driven disease. Because E6 and E7 are usually maintained in cervical tumors even as other viral genes are lost, they represent attractive therapeutic targets, and compounds that reduce E6 protein levels could complement existing prevention and treatment strategies, from vaccination and screening to surgery, radiotherapy, and chemotherapy. The microRNA dimension adds a further layer of potential value, since circulating miR-34a, miR-218, and related species have been proposed as early, minimally invasive biomarkers of cervical carcinogenesis, and microRNA profiles could in principle serve as pharmacodynamic readouts of a compound’s activity.

The authors and outside observers alike emphasize the preliminary nature of the work. All experiments were conducted in a single HPV16-positive cell line with one normal comparator, over exposure windows of 24 and 48 hours, and the study did not generate or analyze external datasets. Whether the E6 reduction results from effects on viral gene transcription, on E6 messenger RNA stability, on protein translation, or on protein degradation pathways, and whether the microRNA changes drive the cytotoxicity or merely accompany it, are questions the current design cannot answer. The researchers state that further studies in additional cellular models and mechanistic systems are required to clarify the underlying pathways. Translational development would also need to confront chrysin’s bioavailability limitations and establish efficacy and safety in animal models before any clinical relevance could be assessed. For now, the study offers a carefully documented snapshot of a common dietary flavonoid simultaneously touching a viral oncoprotein and a network of cancer-related microRNAs in cervical cancer cells, a combination that justifies closer mechanistic scrutiny.

Subject of Research: Effects of the flavonoid chrysin on HPV16 E6 oncoprotein levels and cancer-related microRNA expression in cervical cancer cells

Article Title: Chrysin treatment is associated with altered microrna expression and reduced levels of HPV16 E6 protein in caski cervical cancer cells

Article References: Gholami Fashkhami, M., Habibollahi, H., & Shafighi, S. T. (2026). Chrysin treatment is associated with altered microrna expression and reduced levels of HPV16 E6 protein in caski cervical cancer cells. Medical Oncology, 43(10), Article 257. https://doi.org/10.1007/s12032-026-03381-9

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03381-9

Keywords: chrysin, cervical cancer, HPV16, E6 oncoprotein, microRNA, CaSki cells, flavonoid, miR-34a, miR-218, phytochemical, cell viability, Medical Oncology